Citadel Advisors
YMAB

Citadel Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Citadel Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,000
Closed -$108K – 14315
2025
Q2 		$108K Sell
24,000
-14,400
-38% -$64.7K ﹤0.01% 11273
2025
Q1 		$170K Buy
38,400
+32,800
+586% +$190K ﹤0.01% 10679
2024
Q4 		$43.8K Sell
5,600
-14,700
-72% -$179K ﹤0.01% 12532
2024
Q3 		$267K Buy
20,300
+900
+5% +$11.4K ﹤0.01% 9558
2024
Q2 		$234K Buy
19,400
+8,800
+83% +$119K ﹤0.01% 9607
2024
Q1 		$172K Buy
10,600
+9,000
+563% +$121K ﹤0.01% 10554
2023
Q4 		$10.9K Sell
1,600
-1,300
-45% -$7.52K ﹤0.01% 13076
2023
Q3 		$15.8K Sell
2,900
-2,200
-43% -$12.8K ﹤0.01% 12803
2023
Q2 		$34.6K Sell
5,100
-3,600
-41% -$27K ﹤0.01% 12209
2023
Q1 		$43.6K Buy
8,700
+4,300
+98% +$17.6K ﹤0.01% 12340
2022
Q4 		$21.5K Sell
4,400
-48,400
-92% -$352K ﹤0.01% 13090
2022
Q3 		$761K Sell
52,800
-37,500
-42% -$621K ﹤0.01% 7583
2022
Q2 		$1.37M Sell
90,300
-89,800
-50% -$1.05M ﹤0.01% 6329
2022
Q1 		$2.14M Buy
+180,100
New +$1.85M ﹤0.01% 5946

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's YMAB Position: Q3 2025 in Review

Citadel Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 207,642 shares — an estimated $936K sold.

Citadel Advisors first reported a position in YMAB in Q4 2019 and held it in 22 quarters. The position peaked at $5.92M in Q2 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Citadel Advisors reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 207,642 Y-mAbs Therapeutics shares in Q3 2025, an estimated $936K.
  • Citadel Advisors first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 22 quarters.
  • Citadel Advisors's Y-mAbs Therapeutics position peaked at $5.92M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.